Tumour heterogeneity

Definition

Tumour heterogeneity describes differences between tumours of the same type in different patients, and between cancer cells within a tumour. Both can lead to different responses to therapy. Genetic and epigenetic differences between cancer cells within a tumour might explain why some tumour cells remain present in the patient after cancer treatment has finished.

Latest Research and Reviews

  • Research | | open

    Resistance to BRAFV600E inhibitors often occurs in melanoma patients. Here, the authors describe a potential mechanism of acquired drug resistance mediated by tumor-associated B cells-derived IGF-1.

    • Rajasekharan Somasundaram
    • , Gao Zhang
    • , Mizuho Fukunaga-Kalabis
    • , Michela Perego
    • , Clemens Krepler
    • , Xiaowei Xu
    • , Christine Wagner
    • , Denitsa Hristova
    • , Jie Zhang
    • , Tian Tian
    • , Zhi Wei
    • , Qin Liu
    • , Kanika Garg
    • , Johannes Griss
    • , Rufus Hards
    • , Margarita Maurer
    • , Christine Hafner
    • , Marius Mayerhöfer
    • , Georgios Karanikas
    • , Ahmad Jalili
    • , Verena Bauer-Pohl
    • , Felix Weihsengruber
    • , Klemens Rappersberger
    • , Josef Koller
    • , Roland Lang
    • , Courtney Hudgens
    • , Guo Chen
    • , Michael Tetzlaff
    • , Lawrence Wu
    • , Dennie Tompers Frederick
    • , Richard A. Scolyer
    • , Georgina V. Long
    • , Manashree Damle
    • , Courtney Ellingsworth
    • , Leon Grinman
    • , Harry Choi
    • , Brian J. Gavin
    • , Margaret Dunagin
    • , Arjun Raj
    • , Nathalie Scholler
    • , Laura Gross
    • , Marilda Beqiri
    • , Keiryn Bennett
    • , Ian Watson
    • , Helmut Schaider
    • , Michael A. Davies
    • , Jennifer Wargo
    • , Brian J. Czerniecki
    • , Lynn Schuchter
    • , Dorothee Herlyn
    • , Keith Flaherty
    • , Meenhard Herlyn
    •  & Stephan N. Wagner
  • Reviews | | open

    Based on a consensus conference of experts in the evolution and ecology of cancer, this article proposes a framework for classifying tumours that includes four evolutionary and ecological processes: neoplastic cell diversity and changes over time in that diversity, hazards to cell survival and available resources.

    • Carlo C. Maley
    • , Athena Aktipis
    • , Trevor A. Graham
    • , Andrea Sottoriva
    • , Amy M. Boddy
    • , Michalina Janiszewska
    • , Ariosto S. Silva
    • , Marco Gerlinger
    • , Yinyin Yuan
    • , Kenneth J. Pienta
    • , Karen S. Anderson
    • , Robert Gatenby
    • , Charles Swanton
    • , David Posada
    • , Chung-I Wu
    • , Joshua D. Schiffman
    • , E. Shelley Hwang
    • , Kornelia Polyak
    • , Alexander R. A. Anderson
    • , Joel S. Brown
    • , Mel Greaves
    •  & Darryl Shibata
  • Research | | open

    Immune checkpoint blockade (ICB) therapies can unleash anti-tumour T-cell responses. Here the authors show, by integrating MHC tetramer multiplexing, mass cytometry and high-dimensional analyses, that neoantigen-specific, tumour-infiltrating T cells are highly heterogeneous and are subjected to ICB modulations.

    • M. Fehlings
    • , Y. Simoni
    • , H. L. Penny
    • , E. Becht
    • , C. Y. Loh
    • , M. M. Gubin
    • , J. P. Ward
    • , S. C. Wong
    • , R. D. Schreiber
    •  & E. W. Newell

News and Comment